# Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Study · id `cardio:ct-nct03608033` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03608033](<https://clinicaltrials.gov/study/NCT03608033>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03608033

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 360 participants.

## Technical summary

Registry record NCT03608033. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-05 (actual); primary completion 2024-01-12 (actual). Results posted on 2025-12-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 360 participants (enrolled count; ClinicalTrials.gov record NCT03608033, source copy `cardio:ctgov-nct03608033-2025-12-09`, retrieved 2026-10-26)
- Started: 2018-04-05 (actual) (ClinicalTrials.gov record NCT03608033, source copy `cardio:ctgov-nct03608033-2025-12-09`, retrieved 2026-10-26)
- Primary completion: 2024-01-12 (actual) (ClinicalTrials.gov record NCT03608033, source copy `cardio:ctgov-nct03608033-2025-12-09`, retrieved 2026-10-26)
- Completion: 2024-01-12 (actual) (ClinicalTrials.gov record NCT03608033, source copy `cardio:ctgov-nct03608033-2025-12-09`, retrieved 2026-10-26)
- Results first posted: 2025-12-09 (ClinicalTrials.gov record NCT03608033, source copy `cardio:ctgov-nct03608033-2025-12-09`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Bulgaria; Canada; Czechia; Germany; Greece; Hungary; India; Italy; Lithuania; Poland; Singapore; Slovakia; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT03608033, source copy `cardio:ctgov-nct03608033-2025-12-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03608033-2025-12-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
- Condition: IgA Nephropathy
- Intervention (Biological): OMS721
- Intervention (Other): Vehicle (D5W or saline)
- Lead sponsor: Omeros Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 3e847d7ed05f0cf1398f8848aaccaddf01a71fe8fdcd749d81ba39dfb6b0b337
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
